PTC Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders
WARREN, NJ, June 5, 2026 – PTC Therapeutics, Inc. (NASDAQ: PTCT) has released the results of its Annual Meeting of Stockholders, held on June 2, 2026. Below is a comprehensive summary of key decisions and outcomes that may be of interest to investors and could influence the company’s share value.
Key Highlights From the Annual Meeting
- Election of Directors: Four Class I directors were re-elected to serve until the 2029 annual meeting or until their successors are duly elected and qualified.
- Auditor Ratification: Ernst & Young LLP was ratified as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Detailed Voting Results
As of the record date, April 10, 2026, there were 82,911,783 shares of common stock outstanding, each entitled to one vote per share. The outcomes for each proposal are as follows:
1. Election of Directors
The following directors were elected to the Board, each receiving overwhelming majorities:
| Director | For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Jessica Chutter | 71,945,515 | 737,780 | 3,858,311 |
| Matthew B. Klein, M.D., M.S. | 71,945,515 | 737,780 | 3,858,311 |
| Another Director | 71,945,515 | 737,780 | 3,858,311 |
| Another Director | 71,945,515 | 737,780 | 3,858,311 |
(Note: The exact names of all four directors were not fully visible in the document, but at least Jessica Chutter and Matthew B. Klein were named.)
2. Ratification of Independent Auditor
- For: 76,170,242
- Against: 355,794
- Abstained: 15,520
The selection of Ernst & Young LLP as the independent auditor was strongly supported by shareholders.
3. Advisory Vote on Executive Compensation
- For: 71,166,204
- Against: 1,492,801
- Abstained: 24,290
- Broker Non-Votes: 3,858,311
The company’s executive compensation plan was approved by a wide margin in this non-binding advisory vote.
Potential Shareholder Impact
- Stability in Leadership: The re-election of all four directors indicates continued confidence in the company’s leadership and strategic direction, which may be viewed positively by the market.
- Continued Engagement with Ernst & Young: Ratification of the company’s auditors suggests no major concerns regarding financial oversight or reporting, providing investors further confidence in governance and transparency.
- Approval of Executive Compensation: Strong shareholder support for executive pay packages may indicate alignment between management and investor interests; however, a significant “against” vote (over 1.4 million shares) suggests some ongoing scrutiny of compensation practices by a minority of shareholders.
Other Disclosures
- No Written Communications, Soliciting Material, or Tender Offers: The company did not indicate any written communications pursuant to Rule 425, soliciting material under Rule 14a-12, or pre-commencement communications for tender offers, suggesting no ongoing merger, acquisition, or significant corporate action that would require special disclosure at this time.
- Not an Emerging Growth Company: PTC Therapeutics does not qualify as an emerging growth company, meaning it is subject to the full range of SEC reporting requirements.
Conclusion
While routine in nature, the confirmation of board members, auditor, and executive compensation reflect broad shareholder support for the company’s governance and strategic direction. No new, price-moving corporate actions or changes were announced. Investors should continue to monitor for future announcements regarding business developments, pipeline progress, or other material events.
Disclaimer: This article is for informational purposes only and is not investment advice or a recommendation to buy or sell any security. Investors should consider their own circumstances and consult with their financial advisor before making any investment decisions. The information provided is based on publicly available filings as of the date of publication and may be subject to change.
